Maini C L, Sciuto R, Tofani A, Ferraironi A, Carapella C M, Occhipinti E, Mottolese M, Crecco M
Department of Nuclear Medicine, Regina Elená National Cancer Institute, Rome, Italy.
Nucl Med Commun. 1995 Sep;16(9):756-66. doi: 10.1097/00006231-199509000-00006.
This study evaluates the in vivo visualization of somatostatin (SS) receptors in central nervous system (CNS) tumours using 111In-octreotide imaging and discusses the clinical implications. Ninety-five patients with histologically confirmed diagnosis of CNS tumours were imaged 2-4 and 24 h after the intravenous injection of 111-185 MBq of 111In-octreotide. An uptake index was computed using tumour/non-tumour ratios evaluated using a standard region-of-interest method. Semi-quantitative immunohistochemical studies of SS binding sites were performed on frozen tumour sections. All meningiomas, most pituitary adenomas and many glial tumours showed a positive scan, whereas all neurinomas, craniopharingiomas and ependymomas had negative receptor scans. Radio-octreotide uptake varied among the SS receptor positive CNS tumours: very intense in meningioma, intermediate in pituitary adenoma and of a low grade in glioma. The results of immunohistochemical studies confirmed the scintigraphic findings in all cases. We believe 111In-octreotide is a suitable radiopharmaceutical for characterizing CNS tumours in vivo as SS receptor positive or negative. This new neuronuclear imaging technique may be useful for differential diagnosis in selected cases, for post-surgical follow-up and in the assessment of differentiation in glial tumours.
本研究采用111In-奥曲肽显像评估中枢神经系统（CNS）肿瘤中生长抑素（SS）受体的体内可视化情况，并探讨其临床意义。95例经组织学确诊的CNS肿瘤患者在静脉注射111～185MBq的111In-奥曲肽后2～4小时及24小时进行显像。使用标准感兴趣区方法评估肿瘤/非肿瘤比值计算摄取指数。对冰冻肿瘤切片进行SS结合位点的半定量免疫组织化学研究。所有脑膜瘤、大多数垂体腺瘤和许多神经胶质瘤扫描呈阳性，而所有神经鞘瘤、颅咽管瘤和室管膜瘤受体扫描呈阴性。放射性奥曲肽摄取在SS受体阳性的CNS肿瘤中各不相同：在脑膜瘤中非常强烈，在垂体腺瘤中中等，在神经胶质瘤中程度较低。免疫组织化学研究结果在所有病例中均证实了闪烁显像结果。我们认为111In-奥曲肽是一种适合在体内将CNS肿瘤表征为SS受体阳性或阴性的放射性药物。这种新的核医学成像技术可能对某些病例的鉴别诊断、术后随访以及神经胶质瘤分化评估有用。
